REG - BioPharma Credit PLC - UPDATE ON INVESTMENT

Biopharma CreditAnnouncement

28/05/2024 08:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240528:nRSb0768Qa&default-theme=true

RNS Number : 0768Q  BioPharma Credit PLC  28 May 2024

28 May 2024

 

BIOPHARMA CREDIT PLC

 

UPDATE ON INVESTMENT

 

BioPharma Credit PLC (LSE: BPCR) notes the update on the UK CMA (Competition
and Markets Authority) website made on 24 May 2024 regarding the status of
its review of the acquisition of LumiraDx by Roche.  The updated website can
be found in its entirety at: UK CMA Roche / LumiraDx merger inquiry.
(https://www.gov.uk/cma-cases/roche-slash-lumiradx-merger-inquiry)

 

The acquisition of LumiraDx by Roche continues to undergo the standard process
to receive antitrust and regulatory reviews.  At this time, Pharmakon
Advisors, LP cannot comment beyond what has been made public by the CMA and
the companies involved in the transaction.

 

Pharmakon Advisors, LP is continuing to actively monitor the situation and
will provide any updates in due course.

 

 

Enquiries

Buchanan

David Rydell / Mark Court / Jamie Hooper / Henry Wilson

+44 (0) 20 7466 5000

biopharmacredit@buchanan.uk.com (mailto:biopharmacredit@buchanan.uk.com)

Notes to Editors

BioPharma Credit PLC is London's only specialist debt investor to the life
sciences industry and joined the LSE in March 2017. BioPharma Credit
PLC seeks to provide long-term shareholder returns, principally in the form
of sustainable income distributions from exposure to the life sciences
industry. BioPharma Credit PLC seeks to achieve this objective primarily
through investments in debt assets secured by royalties or other cash flows
derived from the sales of approved life sciences products.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDAPMRTMTMTMRI